We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Steven Madden (SHOO) Thrives on Solid E-Commerce Performance
Read MoreHide Full Article
Fashion-footwear dealer Steven Madden, Ltd. (SHOO - Free Report) has been tracking up the charts of late, thanks to immense strength in its e-commerce business. The e-commerce business, which has been working well for various industry players amid the coronavirus pandemic, has been a bright spot for Steven Madden too. Impressively, the company’s shares have been gaining traction. Over the course of a month, the company has gained 22.6% against the industry’s 1.4% dip.
We note that revenues on stevemadden.com surged 82% during the third quarter of 2020. This was up from 72% increase registered in the same quarter a year ago. Gains from increased investment in digital marketing and robust consumer reception of capabilities such as try before you buy have been contributing to performance. Further, digital sales grew 63.3% in the quarter. Notably, this marked the company’s second straight quarter of over 80% year-over-year increase in e-commerce. In the preceding quarter, Steven Madden registered growth of about 88%.
Robust growth in the company’s e-commerce channel has helped post better-than-expected results in third-quarter 2020. Although the coronavirus pandemic continues to hurt the company’s business, the results significantly surpassed management’s expectations. Its actions, including adjusting merchandise mix, enhancing digital initiatives and managing expense structure have aided it to maneuver through the pandemic-induced challenges.
Despite such positives, the company has been grappling with its sluggish wholesale business for a while, which continued in the third quarter of 2020. Decline in the wholesale footwear and accessories/apparel revenues have been marring the unit’s performance. During the third quarter, revenues for the Wholesale business tumbled 32.7%, reflecting decreases in wholesale footwear and accessories/apparel revenues.
Management said that the Wholesale business will remain under pressure owing to the adverse impacts of the pandemic. Although it anticipates sequential improvement in fourth-quarter 2020 on continued recovery in its flagship brand in both footwear and handbags, wholesale revenues are likely to decline in high-teens percentage year over year. Also, its Retail business sales are expected to decline in high-teens percentage in the fourth quarter. Decline in both the Wholesale and Retail segments might hurt the overall top-line results.
Bottom Line
Although top-line concerns remain mainly due to the adverse impacts of coronavirus, management is making every effort to bring the company back on growth trajectory. Steven Madden also remains encouraged about strength in its brands, pristine balance sheet and a robust business model. Continued momentum in the company’s e-commerce might fix its top-line issue going forward. Encouragingly, Steven Madden currently displays a Zacks Rank #3 (Hold).
Deckers (DECK - Free Report) has an expected long-term earnings growth rate of 18.6% and a Zacks Rank#2 (Buy).
Rent-A-Center has delivered an earnings surprise of 12.9% in the last four quarters, on average. The company currently has a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Steven Madden (SHOO) Thrives on Solid E-Commerce Performance
Fashion-footwear dealer Steven Madden, Ltd. (SHOO - Free Report) has been tracking up the charts of late, thanks to immense strength in its e-commerce business. The e-commerce business, which has been working well for various industry players amid the coronavirus pandemic, has been a bright spot for Steven Madden too. Impressively, the company’s shares have been gaining traction. Over the course of a month, the company has gained 22.6% against the industry’s 1.4% dip.
We note that revenues on stevemadden.com surged 82% during the third quarter of 2020. This was up from 72% increase registered in the same quarter a year ago. Gains from increased investment in digital marketing and robust consumer reception of capabilities such as try before you buy have been contributing to performance. Further, digital sales grew 63.3% in the quarter. Notably, this marked the company’s second straight quarter of over 80% year-over-year increase in e-commerce. In the preceding quarter, Steven Madden registered growth of about 88%.
Robust growth in the company’s e-commerce channel has helped post better-than-expected results in third-quarter 2020. Although the coronavirus pandemic continues to hurt the company’s business, the results significantly surpassed management’s expectations. Its actions, including adjusting merchandise mix, enhancing digital initiatives and managing expense structure have aided it to maneuver through the pandemic-induced challenges.
Despite such positives, the company has been grappling with its sluggish wholesale business for a while, which continued in the third quarter of 2020. Decline in the wholesale footwear and accessories/apparel revenues have been marring the unit’s performance. During the third quarter, revenues for the Wholesale business tumbled 32.7%, reflecting decreases in wholesale footwear and accessories/apparel revenues.
Management said that the Wholesale business will remain under pressure owing to the adverse impacts of the pandemic. Although it anticipates sequential improvement in fourth-quarter 2020 on continued recovery in its flagship brand in both footwear and handbags, wholesale revenues are likely to decline in high-teens percentage year over year. Also, its Retail business sales are expected to decline in high-teens percentage in the fourth quarter. Decline in both the Wholesale and Retail segments might hurt the overall top-line results.
Bottom Line
Although top-line concerns remain mainly due to the adverse impacts of coronavirus, management is making every effort to bring the company back on growth trajectory. Steven Madden also remains encouraged about strength in its brands, pristine balance sheet and a robust business model. Continued momentum in the company’s e-commerce might fix its top-line issue going forward. Encouragingly, Steven Madden currently displays a Zacks Rank #3 (Hold).
Eye These Hot Stocks
NIKE (NKE - Free Report) has an expected long-term earnings growth rate of 16.7% and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Deckers (DECK - Free Report) has an expected long-term earnings growth rate of 18.6% and a Zacks Rank#2 (Buy).
Rent-A-Center has delivered an earnings surprise of 12.9% in the last four quarters, on average. The company currently has a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>